THE USE OF ANTIFIBRINOLYTICS IN HIP TRAUMA SURGERY IN A PUBLIC HEALTH SYSTEM: A PROSPECTIVE STUDY
To evaluate the use of tranexamic acid (TXA) and ε-aminocaproic acid (EACA) in reducing blood loss in hip and proximal femur trauma surgery. Prospective study with 49 patients surgically treated in a trauma hospital between Nov/2015 and Feb/2017. The patients were divided in two groups: TXA (n = 24)...
Gespeichert in:
| Veröffentlicht in: | Acta ortopedica brasileira 2021-11, Vol.29 (6), p.304-307 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 307 |
|---|---|
| container_issue | 6 |
| container_start_page | 304 |
| container_title | Acta ortopedica brasileira |
| container_volume | 29 |
| creator | Oliveira, José Alberto Alves Brito, Gabriella Cristina Coelho DE Bezerra, Francisca Magna Prado Carvalho, Carlos Alfredo DE Alencar, Jonatas Brito DE Ibiapina, Roberto César Pontes |
| description | To evaluate the use of tranexamic acid (TXA) and ε-aminocaproic acid (EACA) in reducing blood loss in hip and proximal femur trauma surgery.
Prospective study with 49 patients surgically treated in a trauma hospital between Nov/2015 and Feb/2017. The patients were divided in two groups: TXA (n = 24) and EACA (n = 25). The comparison was made according to gender, age at the time of surgery, ASA, fracture and surgery type, estimated blood loss during surgical approach, hemoglobin and hematocrit levels pre and post-operative, and pharmacological cost. The data was processed using SPSS 22.0 with significance level of p < 0,05.
No significant difference was found in the variables age, gender, ASA and estimated blood loss during surgical approach. No patient needed blood transfusion. When evaluated post-operatively, the hemoglobin and hematocrit values decrease had no significant difference between the antifibrinolytics (p > 0.05). When analyzing total cost for both pharmacological agents, higher cost was observed in EACA than in TXA (US$ 16.09 - US$ 2.73), resulting in a US$ 13.36 addition per patient.
Antifibrinolytic use was efficient on lowering the total blood loss, without the need of blood transfusion. |
| doi_str_mv | 10.1590/1413-785220212906244502 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_crossref_primary_10_1590_1413_785220212906244502</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><scielo_id>S1413_78522021000600304</scielo_id><doaj_id>oai_doaj_org_article_7b7a74ebcced41c7a11a61dcfe92d764</doaj_id><sourcerecordid>2605225975</sourcerecordid><originalsourceid>FETCH-LOGICAL-c522t-926473af7b2229d5b240eb67bb86bd620eecedf4afc782c3141480284fea2d5d3</originalsourceid><addsrcrecordid>eNpVUl1v0zAUjRCIjcFfAD_yku3aceyYB6QspIulrq3ygdQny3GckSpttqRF4t8voeugT7buPefcc6-O43zBcI19ATeYYs_lgU8IEEwEMEKpD-SNc4kDEC6lwN6O_xPqwvkwDBsAn3uBeO9ceDSgAgS9dHSexKjIYrScoXCRy5m8TeViOV_nMsqQXKBErlCehsV9iLIivYvT9VQN0aq4ncsIJXE4zxOUrbM8vv821dNltoqjXP6MUZYXP9YfnXe1bgf76eW9copZnEeJO1_eySicu2bcYu8Kwij3dM1LQoio_JJQsCXjZRmwsmIErDW2qqmuDQ-I8cbdaAAkoLXVpPIr78qRR92q0xv12Ddb3f9RnW7U30LXPyjd7xvTWsVLrjm1pRkVKTZcY6wZrkxtBak4o6PW9VFrMI1tO7XpDv1uNK-y6aTqdHgAYAAeTITvR8LjodzaytjdvtftmYvzzq75pR663ypggL1gEvj6ItB3Twc77NW2GYxtW72z3WFQhME40xfcH6H8CDV9Nwy9rV_HYFBTOtSZyX_pGJmf_3f5yjvFwXsGr2arFA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2605225975</pqid></control><display><type>article</type><title>THE USE OF ANTIFIBRINOLYTICS IN HIP TRAUMA SURGERY IN A PUBLIC HEALTH SYSTEM: A PROSPECTIVE STUDY</title><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Oliveira, José Alberto Alves ; Brito, Gabriella Cristina Coelho DE ; Bezerra, Francisca Magna Prado ; Carvalho, Carlos Alfredo DE ; Alencar, Jonatas Brito DE ; Ibiapina, Roberto César Pontes</creator><creatorcontrib>Oliveira, José Alberto Alves ; Brito, Gabriella Cristina Coelho DE ; Bezerra, Francisca Magna Prado ; Carvalho, Carlos Alfredo DE ; Alencar, Jonatas Brito DE ; Ibiapina, Roberto César Pontes</creatorcontrib><description>To evaluate the use of tranexamic acid (TXA) and ε-aminocaproic acid (EACA) in reducing blood loss in hip and proximal femur trauma surgery.
Prospective study with 49 patients surgically treated in a trauma hospital between Nov/2015 and Feb/2017. The patients were divided in two groups: TXA (n = 24) and EACA (n = 25). The comparison was made according to gender, age at the time of surgery, ASA, fracture and surgery type, estimated blood loss during surgical approach, hemoglobin and hematocrit levels pre and post-operative, and pharmacological cost. The data was processed using SPSS 22.0 with significance level of p < 0,05.
No significant difference was found in the variables age, gender, ASA and estimated blood loss during surgical approach. No patient needed blood transfusion. When evaluated post-operatively, the hemoglobin and hematocrit values decrease had no significant difference between the antifibrinolytics (p > 0.05). When analyzing total cost for both pharmacological agents, higher cost was observed in EACA than in TXA (US$ 16.09 - US$ 2.73), resulting in a US$ 13.36 addition per patient.
Antifibrinolytic use was efficient on lowering the total blood loss, without the need of blood transfusion.</description><identifier>ISSN: 1413-7852</identifier><identifier>ISSN: 1809-4406</identifier><identifier>EISSN: 1809-4406</identifier><identifier>DOI: 10.1590/1413-785220212906244502</identifier><identifier>PMID: 34849094</identifier><language>eng</language><publisher>Brazil: ATHA EDITORA</publisher><subject>Anti-Fibrinolytic ; Hip Fractures ; Original ; ORTHOPEDICS ; Surgery</subject><ispartof>Acta ortopedica brasileira, 2021-11, Vol.29 (6), p.304-307</ispartof><rights>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c522t-926473af7b2229d5b240eb67bb86bd620eecedf4afc782c3141480284fea2d5d3</citedby><cites>FETCH-LOGICAL-c522t-926473af7b2229d5b240eb67bb86bd620eecedf4afc782c3141480284fea2d5d3</cites><orcidid>0000-0002-8609-2385 ; 0000-0003-3318-5067 ; 0000-0003-2382-8532 ; 0000-0002-6424-1490 ; 0000-0002-9524-7625 ; 0000-0001-8695-7900</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601384/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601384/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2095,27903,27904,53770,53772</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34849094$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Oliveira, José Alberto Alves</creatorcontrib><creatorcontrib>Brito, Gabriella Cristina Coelho DE</creatorcontrib><creatorcontrib>Bezerra, Francisca Magna Prado</creatorcontrib><creatorcontrib>Carvalho, Carlos Alfredo DE</creatorcontrib><creatorcontrib>Alencar, Jonatas Brito DE</creatorcontrib><creatorcontrib>Ibiapina, Roberto César Pontes</creatorcontrib><title>THE USE OF ANTIFIBRINOLYTICS IN HIP TRAUMA SURGERY IN A PUBLIC HEALTH SYSTEM: A PROSPECTIVE STUDY</title><title>Acta ortopedica brasileira</title><addtitle>Acta Ortop Bras</addtitle><description>To evaluate the use of tranexamic acid (TXA) and ε-aminocaproic acid (EACA) in reducing blood loss in hip and proximal femur trauma surgery.
Prospective study with 49 patients surgically treated in a trauma hospital between Nov/2015 and Feb/2017. The patients were divided in two groups: TXA (n = 24) and EACA (n = 25). The comparison was made according to gender, age at the time of surgery, ASA, fracture and surgery type, estimated blood loss during surgical approach, hemoglobin and hematocrit levels pre and post-operative, and pharmacological cost. The data was processed using SPSS 22.0 with significance level of p < 0,05.
No significant difference was found in the variables age, gender, ASA and estimated blood loss during surgical approach. No patient needed blood transfusion. When evaluated post-operatively, the hemoglobin and hematocrit values decrease had no significant difference between the antifibrinolytics (p > 0.05). When analyzing total cost for both pharmacological agents, higher cost was observed in EACA than in TXA (US$ 16.09 - US$ 2.73), resulting in a US$ 13.36 addition per patient.
Antifibrinolytic use was efficient on lowering the total blood loss, without the need of blood transfusion.</description><subject>Anti-Fibrinolytic</subject><subject>Hip Fractures</subject><subject>Original</subject><subject>ORTHOPEDICS</subject><subject>Surgery</subject><issn>1413-7852</issn><issn>1809-4406</issn><issn>1809-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVUl1v0zAUjRCIjcFfAD_yku3aceyYB6QspIulrq3ygdQny3GckSpttqRF4t8voeugT7buPefcc6-O43zBcI19ATeYYs_lgU8IEEwEMEKpD-SNc4kDEC6lwN6O_xPqwvkwDBsAn3uBeO9ceDSgAgS9dHSexKjIYrScoXCRy5m8TeViOV_nMsqQXKBErlCehsV9iLIivYvT9VQN0aq4ncsIJXE4zxOUrbM8vv821dNltoqjXP6MUZYXP9YfnXe1bgf76eW9copZnEeJO1_eySicu2bcYu8Kwij3dM1LQoio_JJQsCXjZRmwsmIErDW2qqmuDQ-I8cbdaAAkoLXVpPIr78qRR92q0xv12Ddb3f9RnW7U30LXPyjd7xvTWsVLrjm1pRkVKTZcY6wZrkxtBak4o6PW9VFrMI1tO7XpDv1uNK-y6aTqdHgAYAAeTITvR8LjodzaytjdvtftmYvzzq75pR663ypggL1gEvj6ItB3Twc77NW2GYxtW72z3WFQhME40xfcH6H8CDV9Nwy9rV_HYFBTOtSZyX_pGJmf_3f5yjvFwXsGr2arFA</recordid><startdate>20211101</startdate><enddate>20211101</enddate><creator>Oliveira, José Alberto Alves</creator><creator>Brito, Gabriella Cristina Coelho DE</creator><creator>Bezerra, Francisca Magna Prado</creator><creator>Carvalho, Carlos Alfredo DE</creator><creator>Alencar, Jonatas Brito DE</creator><creator>Ibiapina, Roberto César Pontes</creator><general>ATHA EDITORA</general><general>Sociedade Brasileira de Ortopedia e Traumatologia</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>GPN</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-8609-2385</orcidid><orcidid>https://orcid.org/0000-0003-3318-5067</orcidid><orcidid>https://orcid.org/0000-0003-2382-8532</orcidid><orcidid>https://orcid.org/0000-0002-6424-1490</orcidid><orcidid>https://orcid.org/0000-0002-9524-7625</orcidid><orcidid>https://orcid.org/0000-0001-8695-7900</orcidid></search><sort><creationdate>20211101</creationdate><title>THE USE OF ANTIFIBRINOLYTICS IN HIP TRAUMA SURGERY IN A PUBLIC HEALTH SYSTEM: A PROSPECTIVE STUDY</title><author>Oliveira, José Alberto Alves ; Brito, Gabriella Cristina Coelho DE ; Bezerra, Francisca Magna Prado ; Carvalho, Carlos Alfredo DE ; Alencar, Jonatas Brito DE ; Ibiapina, Roberto César Pontes</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c522t-926473af7b2229d5b240eb67bb86bd620eecedf4afc782c3141480284fea2d5d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Anti-Fibrinolytic</topic><topic>Hip Fractures</topic><topic>Original</topic><topic>ORTHOPEDICS</topic><topic>Surgery</topic><toplevel>online_resources</toplevel><creatorcontrib>Oliveira, José Alberto Alves</creatorcontrib><creatorcontrib>Brito, Gabriella Cristina Coelho DE</creatorcontrib><creatorcontrib>Bezerra, Francisca Magna Prado</creatorcontrib><creatorcontrib>Carvalho, Carlos Alfredo DE</creatorcontrib><creatorcontrib>Alencar, Jonatas Brito DE</creatorcontrib><creatorcontrib>Ibiapina, Roberto César Pontes</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SciELO</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Acta ortopedica brasileira</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Oliveira, José Alberto Alves</au><au>Brito, Gabriella Cristina Coelho DE</au><au>Bezerra, Francisca Magna Prado</au><au>Carvalho, Carlos Alfredo DE</au><au>Alencar, Jonatas Brito DE</au><au>Ibiapina, Roberto César Pontes</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>THE USE OF ANTIFIBRINOLYTICS IN HIP TRAUMA SURGERY IN A PUBLIC HEALTH SYSTEM: A PROSPECTIVE STUDY</atitle><jtitle>Acta ortopedica brasileira</jtitle><addtitle>Acta Ortop Bras</addtitle><date>2021-11-01</date><risdate>2021</risdate><volume>29</volume><issue>6</issue><spage>304</spage><epage>307</epage><pages>304-307</pages><issn>1413-7852</issn><issn>1809-4406</issn><eissn>1809-4406</eissn><abstract>To evaluate the use of tranexamic acid (TXA) and ε-aminocaproic acid (EACA) in reducing blood loss in hip and proximal femur trauma surgery.
Prospective study with 49 patients surgically treated in a trauma hospital between Nov/2015 and Feb/2017. The patients were divided in two groups: TXA (n = 24) and EACA (n = 25). The comparison was made according to gender, age at the time of surgery, ASA, fracture and surgery type, estimated blood loss during surgical approach, hemoglobin and hematocrit levels pre and post-operative, and pharmacological cost. The data was processed using SPSS 22.0 with significance level of p < 0,05.
No significant difference was found in the variables age, gender, ASA and estimated blood loss during surgical approach. No patient needed blood transfusion. When evaluated post-operatively, the hemoglobin and hematocrit values decrease had no significant difference between the antifibrinolytics (p > 0.05). When analyzing total cost for both pharmacological agents, higher cost was observed in EACA than in TXA (US$ 16.09 - US$ 2.73), resulting in a US$ 13.36 addition per patient.
Antifibrinolytic use was efficient on lowering the total blood loss, without the need of blood transfusion.</abstract><cop>Brazil</cop><pub>ATHA EDITORA</pub><pmid>34849094</pmid><doi>10.1590/1413-785220212906244502</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0002-8609-2385</orcidid><orcidid>https://orcid.org/0000-0003-3318-5067</orcidid><orcidid>https://orcid.org/0000-0003-2382-8532</orcidid><orcidid>https://orcid.org/0000-0002-6424-1490</orcidid><orcidid>https://orcid.org/0000-0002-9524-7625</orcidid><orcidid>https://orcid.org/0000-0001-8695-7900</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1413-7852 |
| ispartof | Acta ortopedica brasileira, 2021-11, Vol.29 (6), p.304-307 |
| issn | 1413-7852 1809-4406 1809-4406 |
| language | eng |
| recordid | cdi_crossref_primary_10_1590_1413_785220212906244502 |
| source | DOAJ Directory of Open Access Journals; PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Anti-Fibrinolytic Hip Fractures Original ORTHOPEDICS Surgery |
| title | THE USE OF ANTIFIBRINOLYTICS IN HIP TRAUMA SURGERY IN A PUBLIC HEALTH SYSTEM: A PROSPECTIVE STUDY |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T00%3A41%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=THE%20USE%20OF%20ANTIFIBRINOLYTICS%20IN%20HIP%20TRAUMA%20SURGERY%20IN%20A%20PUBLIC%20HEALTH%20SYSTEM:%20A%20PROSPECTIVE%20STUDY&rft.jtitle=Acta%20ortopedica%20brasileira&rft.au=Oliveira,%20Jos%C3%A9%20Alberto%20Alves&rft.date=2021-11-01&rft.volume=29&rft.issue=6&rft.spage=304&rft.epage=307&rft.pages=304-307&rft.issn=1413-7852&rft.eissn=1809-4406&rft_id=info:doi/10.1590/1413-785220212906244502&rft_dat=%3Cproquest_doaj_%3E2605225975%3C/proquest_doaj_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2605225975&rft_id=info:pmid/34849094&rft_scielo_id=S1413_78522021000600304&rft_doaj_id=oai_doaj_org_article_7b7a74ebcced41c7a11a61dcfe92d764&rfr_iscdi=true |